|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL23R |
Gene summary for IL23R |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL23R | Gene ID | 149233 |
| Gene name | interleukin 23 receptor | |
| Gene Alias | IL23R | |
| Cytomap | 1p31.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q5VWK5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 149233 | IL23R | HCC1 | Human | Liver | HCC | 1.01e-02 | 7.86e-01 | 0.5336 |
| 149233 | IL23R | HCC5 | Human | Liver | HCC | 5.97e-07 | 5.34e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
| GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
| GO:00343411 | Liver | HCC | response to interferon-gamma | 82/7958 | 141/18723 | 1.25e-04 | 1.03e-03 | 82 |
| GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
| GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
| GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
| GO:004578512 | Liver | HCC | positive regulation of cell adhesion | 215/7958 | 437/18723 | 2.53e-03 | 1.22e-02 | 215 |
| GO:000223711 | Liver | HCC | response to molecule of bacterial origin | 181/7958 | 363/18723 | 2.58e-03 | 1.24e-02 | 181 |
| GO:0050688 | Liver | HCC | regulation of defense response to virus | 41/7958 | 69/18723 | 3.38e-03 | 1.54e-02 | 41 |
| GO:00321471 | Liver | HCC | activation of protein kinase activity | 72/7958 | 134/18723 | 5.61e-03 | 2.33e-02 | 72 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL23R | SNV | Missense_Mutation | novel | c.1212A>C | p.Lys404Asn | p.K404N | Q5VWK5 | protein_coding | deleterious(0.01) | benign(0.167) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL23R | SNV | Missense_Mutation | c.1238N>T | p.Gln413Leu | p.Q413L | Q5VWK5 | protein_coding | deleterious(0.02) | possibly_damaging(0.871) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| IL23R | SNV | Missense_Mutation | c.263N>T | p.Trp88Leu | p.W88L | Q5VWK5 | protein_coding | tolerated(0.2) | benign(0.08) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| IL23R | SNV | Missense_Mutation | c.421N>C | p.Asn141His | p.N141H | Q5VWK5 | protein_coding | tolerated(0.29) | benign(0.025) | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD | |
| IL23R | SNV | Missense_Mutation | novel | c.473A>G | p.Tyr158Cys | p.Y158C | Q5VWK5 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IL23R | SNV | Missense_Mutation | novel | c.697G>C | p.Ala233Pro | p.A233P | Q5VWK5 | protein_coding | deleterious(0.02) | possibly_damaging(0.571) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| IL23R | SNV | Missense_Mutation | c.1136C>T | p.Ser379Leu | p.S379L | Q5VWK5 | protein_coding | deleterious(0) | benign(0.436) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IL23R | SNV | Missense_Mutation | novel | c.1678T>A | p.Ser560Thr | p.S560T | Q5VWK5 | protein_coding | tolerated(0.13) | benign(0.031) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| IL23R | SNV | Missense_Mutation | rs767996100 | c.1585N>G | p.Asn529Asp | p.N529D | Q5VWK5 | protein_coding | tolerated(0.65) | benign(0.003) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| IL23R | SNV | Missense_Mutation | rs772901651 | c.1400N>T | p.Ser467Leu | p.S467L | Q5VWK5 | protein_coding | deleterious(0.01) | benign(0.08) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 149233 | IL23R | KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE | celecoxib | CELECOXIB | 23778325 | |
| 149233 | IL23R | KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE | Anti-IL-23 | |||
| 149233 | IL23R | KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE | Tumor necrosis factor alpha (TNF-alpha) inhibitors | 26194362 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |